Theodor-kocher Institute

University College Cardiff Consultants Limited

Other

Millennium Pharmaceuticals Limited

Bernhard Moser

Marcel Loetscher

Shixin Qin

Charles R Mackay

Marlene Brandes Kuchen

Marlène Lymphocyte Biology Section Labof Immunology NatInstof Allergy And Infectious Diseases Brandes

Cytotoxic &#x3b1;&#x3b2; T cells form an essential component in immunity to infections and tumors, and are also implicated in host defense against these challenges. The present disclosure demonstrates the ability of activated &#x3b3;&#x3b4; T cells to cross-present exogenous antigens to CD8&#x3b1;&#x3b2; T cells, a process previously thought to be mediated best by dendritic cells. In particular, the present disclosure provides a method for cross-presentation of antigen derived from tumor cell or microbial organisms such as viruses, bacteria, yeasts, parasites, and the like, or from cells infected with such organisms, to a CD8&#x3b1;&#x3b2; T cell. Still further, the present disclosure provides a method for treatment of a tumor or a chronic or recurrent infectious disease, comprising delivering an antigen-presenting autologous &#x3b3;&#x3b4; T cell population above into a patient requiring such treatment. Still yet further, a method is described for preparing a peptide-specific effector T cell.

Preparation of antigen-presenting human &#x3b3;&#x3b4; T cells and use in immunotherapy

The invention relates to a method for the preparation of efficient antigen-presenting human &#x3b3;&#x3b4; T cells, to the &#x3b3;&#x3b4; T cells prepared by such a method, and to their use in immunotherapy, vaccination, vaccine development and diagnostics. Similar to dendritic cells (DCs) in potency and efficacy, these human &#x3b3;&#x3b4; T cells process antigens and present antigenic peptides to &#x3b1;&#x3b2; T cells and induce antigen-specific responses (proliferation and differentiation) in na&#xef;ve &#x3b1;&#x3b2; T cells. &#x3b3;&#x3b4; T cells are easily purified from peripheral blood, acquire 'maturation' status (expression of essential adhesion, co-stimulatory and major histocompatibility complex molecules) within 1 day of in vitro culture under stimulation and induce strong primary and secondary T helper cell and cytotoxic T cell responses. The &#x3b3;&#x3b4; T cells may be used in a method of treatment of tumors or chronic or recurrent infectious diseases, in identification of novel tumor or pathogen-derived antigens, and in the diagnosis of the immune competence of a patient.

Preparation of antigen-presenting human gamma-delta T cells and use in immunotherapy

The present invention relates to proteins or polypeptides, referred to herein as isolated and/or recombinant mammalian (e.g., human) IP-10/Mig receptor proteins designated CXC Chemokine Receptor 3 (CXCR3) and variants thereof, including those characterized by selective binding of one or more chemokines (e.g., IP-10 and/or Mig), and/or the ability to induce a cellular response (e.g., chemotaxis, exocytosis). Antibodies reactive with CXCR3 receptors can be produced using the proteins or variants thereof or host cells comprising same as immunogen.

Method of inhibiting leukocytes with human CXC chemokine receptor 3 antibody

The invention relates to methods of identifying ligands, and inhibitors (e.g., antagonists) or promoters (e.g., agonists) of receptor function, including methods in which host cells comprising a nucleic acid encoding a CXCR3 or variant thereof are used in an assay to identify and assess the efficacy of ligands, inhibitors or promoters. Inhibitors and promoters of receptor function can be used to modulate receptor activity, permitting selective inhibition of lymphocyte function, particularly of effector cells such as activated T lymphocytes and NK cells for therapeutic purposes.

Method for identifying ligands, inhibitors or promoters of CXC chemokine receptor 3

IP-10/MIG receptor designated CXCR3, nucleic acids and methods of use therefor

The invention relates to isolated and/or recombinant nucleic acids encoding a mammalian (e.g., human) CXCR3 protein and variants thereof, including antisense nucleic acid, recombinant nucleic acid constructs, such as plasmids or retroviral vectors, comprising a nucleic acid which encodes a protein of the present invention or variant thereof, and to host cells comprising a nucleic acid or construct, useful in the production of recombinant proteins. The invention also relates to a method for producing a mammalian (e.g., human) CXCR3 protein.

IP-10/MIG receptor designated CXCR3, nucleic acids, and methods of use therefor

IP-10/Mig receptor designated CXCR3, antibodies, nucleic acids, and methods of use therefor

The present invention relates to methods of identifying ligands, and inhibitors (e.g., antagonists) or promoters (e.g., agonists) of receptor function, including methods in which host cells comprising a nucleic acid encoding a CXCR3 or variant thereof are used in an assay to identify and assess the efficacy of ligands, inhibitors or promoters. Inhibitors and promoters of receptor function can be used to modulate receptor activity, permitting selective inhibition of lymphocyte function, particularly of effector cells such as activated T lymphocytes and NK cells for therapeutic purposes.

Growing community of inventors

Utzenstorf, Switzerland

Bernhard Moser